Moxeza
(moxifloxacin hydrochloride)ApprovedSmall molecule
BayerMoxeza is one of 117 small molecule programs targeting Neutropenia. It is currently in Approved.
3
Indications
15
Total Trials
1
Active Trials
116
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
119 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Moxeza
BayerApproved
Lunsekimig
SanofiPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Astegolimab
RochePhase 3
Tozorakimab
AstraZenecaPhase 3
CM512
KKeymed Biosciences Co.Ltd
Phase 2
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiac Repolarization3 trials
Cataract2 trials
Bacterial Infections1 trial
6 more indications
Chronic Obstructive Pulmonary Disease1 trial
Neutropenia1 trial
Concentration1 trial
COPD1 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[4]
Dec 10, 1999
AVELOX
NDA NDA021085
Nov 30, 2001
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
NDA NDA021277
Apr 15, 2003
VIGAMOX
NDA NDA021598
Nov 19, 2010
MOXEZA
NDA NDA022428
Apr 3, 2015
MOXIFLOXACIN HYDROCHLORIDE
NDA NDA205572
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for moxifloxacin hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]